Targeting RAC1 activity via genetic disruption of PREX2 can enhance sensitivity to MAPK inhibition in BRAF-V600E–driven melanoma in vivo, although pharmacologic targeting of the RAC1 effector p110β also seems capable of enhancing responses to MAPK inhibition in vitro. Here, PREX2 is linked to melanoma.